


What is Claimed is:

1. A compound which has the structure



5

wherein x is 1, 2, 3 or 4; m is 1 or 2; n is 1 or 2;

O is C or N;

A is 0 or S;

Z is 0 or a bond;

10  $R^1$  is H or lower alkyl;

X is CH or N;

R<sup>2</sup> is H, alkyl, alkoxy, halogen, amino or substituted amino;

R<sup>2a</sup>, R<sup>2b</sup> and R<sup>2c</sup> are the same or different and are  
15 selected from H, alkyl, alkoxy, halogen, amino or  
substituted amino;


R<sup>3</sup> is H, alkyl, arylalkyl, aryloxy carbonyl, alkyloxy carbonyl, alkynyloxy carbonyl, alkenyloxy carbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl,  
20 alkyl(halo)aryloxy carbonyl, alkyloxy(halo)aryloxy carbonyl, cycloalkylaryloxy carbonyl, cycloalkyloxyaryloxy carbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroaryl-heteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxy carbonylamino,  
25 aryloxy carbonylamino, heteroaryloxy carbonylamino, heteroaryl-heteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxy carbonyl, cycloheteroalkyloxy carbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl,  
30 alkylaminocarbonyl, arylaminocarbonyl, heteroarylalkenyl, cycloheteroalkylheteroarylalkyl, hydroxyalkyl, alkoxy, alkoxyaryloxy carbonyl, arylalkyloxy carbonyl, alkylaryloxy carbonyl, arylheteroarylalkyl, arylalkylarylalkyl, aryloxyarylalkyl, alkynyloxy carbonyl,

- haloalkoxyaryloxy carbonyl, alkoxycarbonylaryloxy carbonyl, aryloxyaryloxy carbonyl, arylsulfinylaryl carbonyl, arylthioaryl carbonyl, alkoxycarbonylaryloxy carbonyl, arylalkenylloxy carbonyl, heteroaryloxyarylalkyl,
- 5 aryloxyaryl carbonyl, aryloxyarylalkylloxy carbonyl, arylalkenylloxy carbonyl, arylalkyl carbonyl, aryloxyalkylloxy carbonyl arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, alkoxyarylalkyl,
- 10 heteroarylalkoxy carbonyl, arylheteroarylalkyl, alkoxyaryl carbonyl, aryloxyheteroarylalkyl, heteroarylalkylloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylalkoxyarylalkyl, arylcarbonylarylalkyl, alkylaryloxyarylalkyl,
- 15 arylalkoxy carbonyl heteroarylalkyl, heteroarylarylalkyl, arylcarbonyl heteroarylalkyl, heteroaryloxyarylalkyl, arylalkenyl heteroarylalkyl, arylaminoarylalkyl or aminocarbonylarylalkyl;


- Y is  $\text{CO}_2\text{R}^4$  (where  $\text{R}^4$  is H or alkyl, or a prodrug ester) or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure  $\text{P}(\text{O})(\text{OR}^{4a})\text{R}^5$ , (where  $\text{R}^{4a}$  is H or a prodrug ester,  $\text{R}^5$  is alkyl or aryl) or a phosphonic acid of the structure  $\text{P}(\text{O})(\text{OR}^{4a})_2$ , (where  $\text{R}^{4a}$  is H or a prodrug ester);
- 20 including all stereoisomers thereof, prodrug

- 25 esters thereof, and pharmaceutically acceptable salts thereof, with the proviso that where X is CH, A is O, Q is C, Z is O and Y is  $\text{CO}_2\text{R}^4$ , then  $\text{R}^3$  is other than H or alkyl containing 1 to 5 carbons in the normal chain.


- 30 2. A compound having the structure



or




3. The compound as defined in Claim 1 having the structure




5

4. The compound as defined in Claim 1 having structure



or

10



5. The compound as defined in Claim 1 wherein  $(CH_2)_x$  is alkylene, alkenylene, allenyl, or alkynylene.


15

6. The compound as defined in Claim 4 wherein X is CH.

7. The compound as defined in Claim 4 wherein X is N.


20

8. The compound as defined in Claim 1 having the structure



wherein R¹ is alkyl, R³ᵇ is arylalkylamino, aryl-  
 5 arylamino, arylamino, alkoxyarylamino, dialkoxyarylamino, dihaloarylamino or alkylthioarylamino.

9. The compound as defined in Claim 1 having the structure



10

10. The compound as defined in Claim 1 wherein R²ᵃ  
 is alkoxy or H,

(CH₂)ₓ is CH₂, (CH₂)₂, (CH₂)₃, or  $\begin{array}{c} \text{CH}_3 \quad \text{CH}_3 \\ \diagdown \quad \diagup \\ \text{---C---} \end{array}$ , (CH₂)ₘ is CH₂, or

15  $\begin{array}{c} \text{R}^{\text{a}} \\ | \\ \text{---CH---} \end{array}$  (where Rₐ is alkyl or alkenyl), (CH₂)ₙ is CH₂, R¹  
 is lower alkyl, preferably -CH₃, R² is H, R²ᵃ is H, R⁴ is  
 H, X is CH, and R³ is arylalkyloxycarbonyl,  
 arylheteroarylalkyl, aryloxyarylalkyl, arylalkyl,  
 aryloxycarbonyl, haloaryl-oxycarbonyl,  
 20 alkoxyaryloxycarbonyl, alkylaryloxycarbonyl,  
 aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl,  
 heteroaryloxycarbonyl, aryloxyarylcarbonyl,  
 arylalkenyloxycarbonyl, cycloalkylaryloxycarbonyl,  
 arylalkylarylcarbonyl, heteroaryl-heteroarylalkyl,  
 25 cycloalkyloxyaryloxycarbonyl, heteroaryl-  
 heteroarylcarbonyl, alkylaryloxycarbonyl,  
 arylalkylsulfonyl, arylalkenylsulfonyl, alkoxyarylalkyl,  
 arylthiocarbonyl, cycloheteroalkylalkyloxycarbonyl,  
 cycloheteroalkyloxycarbonyl, or polyhaloalkylaryloxy-  
 30 carbonyl, which may be optionally substituted.


11. The compound as defined in Claim 5 wherein X is CH.

5 12. The compound as defined in Claim 5 wherein X is N.


13. The compound as defined in Claim 1 wherein x is 2, m is 1, and n is 1.

10

14. The compound as defined in Claim 1 having the structure




15 15. The compound as defined in Claim 1 having the structure




where  $(CH_2)_n$  is  $CH_2$  or  $\begin{array}{c} CH_3 \\ | \\ -CH- \end{array}$ .







5





10





15









5




10



15









5

10


15




5




10





15








5

















10






15

, where  $R^{3c} =$



$$\begin{array}{c} \text{---} \\ | \\ \text{H}_3\text{C} - \text{C} - \text{CH}_3 \\ | \\ \text{(R)} \end{array}$$
CCCCO  
(R)Cc1oc(C#Nc2ccccc2)c1CCOc3ccc(cc3)CN(C(=O)O)C(=O)Oc4ccc(OC)cc4CC1=C(C2=CC=CC=C2)OC(=N1)C3=CC=CC=C3CCOC4=CC=CC=C4CCOC(=O)N(CCC5=CC=CC=C5)C6=CC=CC=C6












5





10





15









5




10






15














5


where  $R^{3e} =$ 

10




15







5





10





15











5





10










15




5




10




15


where R<sup>3g</sup> =



5






10






15



where  $R^3 =$



5


where  $R^3 =$ 

10

, where  $R^3 =$ 

15










$$\text{Ph} \begin{array}{c} \diagup \text{N} \\ \diagdown \text{O} \end{array} \begin{array}{c} \text{CH}_3 \\ | \end{array} \text{CH}_2 \text{CH}_2 \text{O} \text{C}_6\text{H}_4 \text{CH}_2 \text{N} \begin{array}{c} \text{O} \\ \diagup \end{array} \begin{array}{c} \text{R}^{3h} \\ | \end{array} \text{C} \begin{array}{c} \text{O} \\ \diagdown \end{array} \text{OH}$$





, where  $\text{R}^{3h} =$

Chemical structures of various substituted benzene rings used in the study:


- 1-methyl-3-fluorobenzene
- 1-methyl-3-chlorobenzene
- 1-methyl-3-bromobenzene
- 1-methoxy-3-fluorobenzene
- 1-methoxy-3-chlorobenzene
- 1-methoxy-3-bromobenzene
- 1-ethyl-4-phenylbenzene
- 1-(cyclopropylmethyl)benzene
- 1-(cyclopropylmethoxy)benzene




5



10




(racemate)





where  $R^* = (\pm)\text{-Me}$ ,  $(\pm)\text{ n-Bu}$ ,



5






where  $R^a = (\pm) \text{Et}, (\pm) \text{i-Bu},$







(±)








10









15







5









10






5









10







5









10







5





10





5






10











5














10



































5











17. The compound as defined in Claim 1 having the structure



































5







18. The compound as defined in Claim 1 having the structure











19. The compound as defined in Claim 1 having the structure








20. The compound as defined in Claim 1 having the structure







15











5








10













5







10










5











10

















5









10








5
























5




















10















5







21. The compound as defined in Claim 1 having the structure




22. The compound as defined in Claim 1 having the structure



23. The compound as defined in Claim 1 having the structure




24. The compound as defined in Claim 1 having the structure




5

25. The compound as defined in Claim 1 having the structure




10

26. The compound as defined in Claim 1 having the structure




27. The compound as defined in Claim 1 having the structure




5

28. The compound as defined in Claim 1 having the structure




10

29. The compound as defined in Claim 1 having the structure




15

30. The compound as defined in Claim 1 having the structure




31. The compound as defined in Claim 1 having the structure



5

32. The compound as defined in Claim 1 having the structure



10

33. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

15

34. A method for lowering blood glucose levels which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

20

35. A method for treating diabetes which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

25

36. A method for treating a premalignant disease, an early malignant disease, a malignant disease, or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.



37. A pharmaceutical combination comprising a compound as defined in Claim 1 and a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent, a platelet aggregation inhibitor, and/or an antiosteoporosis agent.

38. The pharmaceutical combination as defined in Claim 37 comprising said compound and an antidiabetic agent.

39. The combination as defined in Claim 38 wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR $\alpha$  agonist, a PPAR  $\gamma$  agonist, a PPAR  $\alpha/\gamma$  dual agonist, an SGLT2 inhibitor, a DP4 inhibitor, an  $\alpha$ P2 inhibitor, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), insulin and/or a meglitinide.

40. The combination as defined in Claim 39 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyrider, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, P32/98 and/or NVP-DPP-728A.

41. The combination as defined in Claim 38 wherein the compound is present in a weight ratio to the antidiabetic agent within the range from about 0.001 to about 100:1.

42. The combination as defined in Claim 37 wherein the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake

inhibitor, a thyroid receptor agonist, an  $\alpha 2$  inhibitor and/or an anorectic agent.

43. The combination as defined in Claim 42 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol.

44. The combination as defined in Claim 37 wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxxygenase inhibitor, or an ACAT inhibitor.

45. The combination as defined in Claim 44 wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, itavastatin, visastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, cholestagel, niacin and/or LY295427.

46. The combination as defined in Claim 44 wherein the compound is present in a weight ratio to the lipid-lowering agent within the range from about 0.001:1 to about 100:1.

47. The combination as defined in Claim 37 wherein the antihypertensive agent is an ACE inhibitor, angiotensin II receptor antagonist, NEP/ACE inhibitor, calcium channel blocker and/or  $\beta$ -adrenergic blocker.

48. The combination as defined in Claim 47 wherein the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril; an NEP/ACE inhibitor which is omapatrilat,  $[S[(R^*, R^*)]]$ -hexahydro-6-

[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat) or CGS 30440;

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;

5 amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or clonidine HCl.

49. The combination as defined in Claim 37 wherein  
10 the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or ifetroban.

50. A method for treating insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels  
15 of free fatty acids or glycerol, hyperlipidemia, obesity, Syndrome X, dysmetabolic syndrome, inflammation, diabetic complications, impaired glucose homeostasis, impaired glucose tolerance, hypertriglyceridemia or atherosclerosis which comprises administering to a  
20 mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 43.

51. A method for treating irritable bowel  
25 syndrome, Crohn's disease, gastric ulceritis or osteoporosis, or psoriasis, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

30 52. The method as defined in Claim 36 wherein the disease is a liposarcoma or an epithelial tumor.

53. The method as defined in Claim 52 wherein the  
35 epithelial tumor is a tumor of the breast, prostate, colon, ovaries, stomach or lung.

54. The method as defined in Claim 36 wherein the disease is ductal carcinoma in situ of the breast, lobular carcinoma in situ of the breast, fibroadenoma of the breast, or prostatic intraepithelial neoplasia.

5